Article Sidebar

pdf
Date Published: 04/03/2024
Abstract Views: 320
Views pdf: 273
DOI: https://doi.org/10.51298/vmj.v536i1.8717
Issue
Vol. 536 No. 1 (2024)
Section
Các bài báo
How to Cite
Võ , N. Y. N. ., Nguyễn, T. H., Võ , T. H. ., & Trần, C. Đông . (2024). COST-EFFECTIVENESS ANALYSIS OF EDOXABAN COMPARED TO OTHER NOACS REGIMENTS IN THE TREATMENT OF VENOUS THROMBOEMBOLISM FROM THE PERSPECTIVE OF VIETNAM HEALTH INSURANCE. Vietnam Medical Journal, 536(1). https://doi.org/10.51298/vmj.v536i1.8717

COST-EFFECTIVENESS ANALYSIS OF EDOXABAN COMPARED TO OTHER NOACS REGIMENTS IN THE TREATMENT OF VENOUS THROMBOEMBOLISM FROM THE PERSPECTIVE OF VIETNAM HEALTH INSURANCE

Ngọc Yến Nhi Võ , Thúy Hằng Nguyễn, Thúy Hằng Võ , Cát Đông Trần

Main Article Content

Abstract

Background: Edoxaban, a novel oral anticoagulant, has been approved by the US Food and Drug Administration for the treatment of venous thromboembolism (VTE) due to its outstanding advantages in terms of efficacy and safety [1]. However, in the same situation with other NOACs, high drug cost of edoxaban is a barrier in clinical prescribing. Therefore, the cost-effectiveness of edoxaban needs to be evaluated to consider appropriate healthcare policies that increase the patient's access to treatment in the context of limited health budgets. Currently, in Vietnam, the cost – effectiveness of edoxaban has not yet been fully studied. Research Methods: Cost-effectiveness analysis has been conducted with modelling study design using Markov model from the Vietnamese healthcare payer perspective. Input parameters were collected from literature review, clinical expert opinion and tender results at the time of the study. Results: LMWH/edoxaban increased QALY when being compared to rivaroxaban and LMWH/dabigatran with 0,032 và 0,042 QALY, respectively  and saved 0.82 million and 0.65 million VND in life-time horizon. Conclusion: From Vietnamese healthcare payer perspective, LMWH/edoxaban was dominant compared to rivaroxaban and LMWH/dabigatran in treatment of VTE.

Article Details

References

1. Prandoni, P., et al., Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. Journal of thrombosis and haemostasis, 2010. 8(11): p. 2575-2577.
2. Khan, F., T. Tritschler, S.R. Kahn, and M.A. Rodger, Venous thromboembolism. The lancet, 2021. 398(10294): p. 64-77.
3. Khan, F., T. Tritschler, S.R. Kahn, and M.A. Rodger, Venous thromboembolism. Lancet, 2021. 398(10294): p. 64-77.
4. Grosse, S.D., et al., The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res, 2016. 137: p. 3-10.
5. Hurst, K.V., J.M. O’Callaghan, and A. Handa, Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vascular Health and Risk Management, 2016: p. 329-335.
6. Stevanović, J., et al., Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PLoS One, 2016. 11(10): p. e0163550.
7. Preblick, R., W.J. Kwong, R.H. White, and S.Z. Goldhaber, Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. Hospital Practice, 2015. 43(5): p. 249-257.
8. Clay, E., et al., Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 2018. 6(1): p. 1495974.
9. Niyomsri, S., M. Nimworapan, W. Wongcharoen, and P. Dilokthornsakul, Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. Int J Environ Res Public Health, 2023. 20(4).
10. Gulati, S. and M.H. Eckman, Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. Ann Intern Med, 2023. 176(1): p. 1-9.